Sign in
GANX Stock Price, Chart, Stats & News
Gain Therapeutics, Inc.
Save
73.36M
Market cap
–
Current P/E
–
Forward P/E
GANX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -4.46% |
ROA | -88.35% |
ROE | -237.54% |
D/E | 0.02x |
Interest coverage ratio | – |
GANX valuation
P/E | – |
P/S | – |
P/B | 3.25x |
P/CF | -2.27x |
P/FCF | -2.65x |
P/OCF | -2.27x |
PEG | -0.64x |
EV multiple | -4.88x |
About
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins.
Similar securities
Based on sector and market capitalization
Report issue